The biopharmaceutical company backed by the corporate venturing units of Pfizer, Novartis and Johnson & Johnson increases the size of its latest round.
Celladon, a biopharmaceutical company backed by multiple corporates, has increased its latest round to $53m on Tuesday, with additional backing from venture firms MPM Capital and LSP Life Sciences Partners. The company had announced a first close at $43m in February.
Celladon was backed in the round by corporate venturing funds for pharma companies – Pfizer Venture Investments, Novartis Venture Funds, and Johnson & Johnson Development Corporation, as well as life science venture funds Hambrecht & Quist Healthcare/Life Sciences Investors…
